Results 251 to 260 of about 103,365 (348)

Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review. [PDF]

Cureus
Ibrahim R, Kambal A, Abdelmajeed MA.
europepmc   +1 more source

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen, Qiu Zhang, Binhong Duan, Xiaohong Wu, Hailong Wan, Binhong Wen, Jie Han, Haixia Liu, Caixian Yang, Weiwei Liu, Qin Du, Lei Kang, Minlu Zhang   +12 more
wiley   +1 more source

Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. [PDF]

Diabetes Obes Metab
Chou YC, Weng SH, Cheng FS, Tseng CH, Hu HY, Liu CH.   +5 more
europepmc   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear.
Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart   +6 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in neuropathic pain: hype or hope? [PDF]

Korean J Pain
Choi JI.
europepmc   +1 more source

Opposite kinetics of L-leucine and L-phenylalanine induced insulin release studies with the perfused rat pancreas [PDF]

, 1972
Landgraf, R., Landgraf-Leurs, M. M. C., Schwarz, K., Scriba, Peter Christian   +3 more
core  

Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim To quantify the relative importance of frequency of administration in basal insulin treatment preferences of people living with type 2 diabetes (T2D) in France and Spain, using a discrete choice experiment (DCE). Materials and Methods A targeted literature review and qualitative patient interviews informed an attributes and levels grid ...
Amy M. Jones, Pam Hallworth, Helen Kendal, Claire Mottershead, Lewis Ormerod, Virginia Pascual, Clémence Antier, Diogo Belbute, Elisabeth de Laguiche, Virginia Bellido   +9 more
wiley   +1 more source

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong, Yawen Zhang, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction. [PDF]

Cardiooncology
Scalia IG, Ibrahim R, Abdelnabi M, Pham HN, Farina JM, Pietri MP, Lee KS, Tamarappoo BK, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source